Research demonstrates these effects prove particularly beneficial in ischemic or hypovascular tissues such as tendons and ligaments where limited blood supply typically impedes healing
This rapidly deactivates the trigger point, providing immediate relief from chronic muscular pain, headaches, neck and shoulder tension, and referred pain syndromes
All products are intended for in vitro research in licensed laboratory environments only
Predrag Sikirics group (School of Medicine, University of Zagreb, 1991 ) Most common experimental dose in animal studies: 10 g/kg intraperitoneally or per os, daily Standard targeted pathways: VEGFR2 angiogenesis, NO synthase , 5-HT2A serotonin receptor, dopamine D2 receptor Clinical program in Croatia halted at Phase 2 (Crohns disease) WADA Prohibited List: added in 2022 to category S0 (Non-Approved Substances) Reference sources (PubMed) Sikiric P
Frequently Asked Questions Is BPC-157 illegal to purchase